From the Editors
In the August issue of The Oncology Pharmacist (TOP), we feature results of a clinical trial presented at the 2018 American Association for Cancer Research meeting, which showed that the addition of the immune checkpoint inhibitor pembrolizumab to chemotherapy yielded significantly longer overall survival and progression-free survival compared with chemotherapy alone in patients with newly diagnosed metastatic nonsquamous non–small-cell lung cancer.
The July issue of The Oncology Nurse-APN/PA (TON) is packed with indispensable news and insights for today’s oncology nurse.
In this issue, we feature a profile of the Taussig Cancer Center, Cleveland Clinic, OH, where, in my capacity as a nurse practitioner in the Department of Hematologic Oncology and Blood Disorders, my primary role is to diagnose and manage patients with multiple myeloma, amyloidosis, and other hematologic disorders.
Results from another clinical trial, ALEX, were also presented at the meeting, and led to alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, being hailed as a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer.
Results 1 - 10 of 62